title: [Adverse effects of intralesional Glucantime in the treatment of cutaneous leishmaniosis].
abstract: OBJECTIVE
  The treatment of cutaneous leishmaniasis used in Tunisia is Glucantime. The aim of this retrospective study was to determine the adverse effects of intralesional Glucantime and to calculate the risk/benefit rate of this treatment.
  
  
  RESULTS
  Adverse effects were observed in 14 cases (5%). For facial lesions, we observed facial staphylococci in 2 cases, stibio-intolerance in 1 case, and a palpebral subcutaneous nodule in 1 case. In limb lesions the complications were: sporotrichoid nodules in 5 cases, vagal malaise (1 case), pyodermitis (1 case), erysipelas (1 case), necrosis (1 case), and urticaria (1 case).
  
  
  CONCLUSIONS
  The adverse effects of intralesional Glucantime are mostly infections, mainly observed in cephalic localization, and stibio-intolerance. For this reason, intralesional injection of Glucantime must be avoided in the cephalic region.
authors.affiliation: Service de Dermatologie, EPS Hédi-Chaker, CHU Hédi-Chaker, 3029 Sfax, Tunisie. masmoudiabd@yahoo.fr
authors.forename: A
authors.initials: A
authors.lastname: Masmoudi
authors.forename: N
authors.initials: N
authors.lastname: Maalej
authors.forename: S
authors.initials: S
authors.lastname: Boudaya
authors.forename: H
authors.initials: H
authors.lastname: Turki
authors.forename: A
authors.initials: A
authors.lastname: Zahaf
mesh_terms: D000293:Adolescent; D000328:Adult; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D004198:Disease Susceptibility; D003875:Drug Eruptions / Q000209:etiology*; D005148:Facial Dermatoses / Q000209:etiology; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D018570:Risk Assessment; D013174:Sporotrichosis / Q000209:etiology; D013207:Staphylococcal Skin Infections / Q000209:etiology; D015163:Superinfection / Q000209:etiology
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate